Tobacco smoking as a risk factor of bronchioloalveolar carcinoma of the lung: pooled analysis of seven case–control studies in the International Lung Cancer Consortium (ILCCO) by Boffetta, Paolo et al.
ORIGINAL PAPER
Tobacco smoking as a risk factor of bronchioloalveolar carcinoma
of the lung: pooled analysis of seven case–control studies
in the International Lung Cancer Consortium (ILCCO)
Paolo Boffetta • Vijayvel Jayaprakash • Ping Yang • Koﬁ Asomaning •
Joshua E. Muscat • Ann G. Schwartz • Zuo-Feng Zhang • Loic Le Marchand •
Michele L. Cote • Shawn M. Stoddard • Hal Morgenstern • Rayjean J. Hung •
David C. Christiani
Received: 9 April 2010/Accepted: 18 October 2010/Published online: 12 November 2010
 The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract
Background The International Lung Cancer Consortium
(ILCCO) was established in 2004, based on the collabo-
ration of research groups leading large molecular epide-
miology studies of lung cancer that are ongoing or have
been recently completed. This framework offered the
opportunity to investigate the role of tobacco smoking in
the development of bronchioloalveolar carcinoma (BAC), a
rare form of lung cancer.
Methods Our pooled data comprised seven case–control
studies from the United States, with detailed information
on tobacco smoking and histology, which contributed 799
cases of BAC and 15,859 controls. We estimated the odds
ratio of BAC for tobacco smoking, using never smokers as
a referent category, after adjustment for age, sex, race, and
study center.
Results The odds ratio of BAC for ever smoking was 2.47
(95% conﬁdence interval [CI] 2.08, 2.93); the risk
increased linearly with duration, amount, and cumulative
cigarette smoking and persisted long after smoking cessa-
tion. The proportion of BAC cases attributable to smoking
was 0.47 (95% CI 0.39, 0.54).
Conclusions This analysis provides a precise estimate of
the risk of BAC for tobacco smoking.
Keywords Lung cancer  Bronchioloalveolar carcinoma 
Tobacco smoking
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Tobacco smoking is the most important cause of lung
cancer, being responsible for an estimated 80–90% of cases
in most populations of the world [1]. The carcinogenic
effect of tobacco smoking on different histological types
has been investigated in several studies, which typically
included the most frequent types: a stronger risk has been
repeatedly reported for squamous cell carcinoma and small
cell carcinoma than for adenocarcinoma [2], while the risk
of large cell carcinoma, which has been investigated less
frequently, seems intermediate [3]. Data on other, rarer
histological types are sparse and often based on a small
series of cases leading to imprecise risk estimates.
Bronchioloalveolar carcinoma (BAC) of the lung is a
form of adenocarcinoma characterized by growth of neo-
plastic cells along the alveolar structures with limited
invasion of the blood vessels, the stroma, or the pleura. A
mucinous and a non-mucinous variants are distinguished,
the latter being more frequent. Distinction between BAC
and other forms of lung adenocarcinoma is often difﬁcult,
and cancers, in particular those of larger size, frequently
display mixed histologies [4]. BAC is considered a rela-
tively infrequent form of lung cancer, but population-based
data on incidence are scant. In the United States, age-
adjusted incidence rates in the 1970s and 1980s were
between 1 and 2 per 100,000, with little differences
between sexes and races [5]. Reviews of series of patients
from single institutions suggested an increase in the pro-
portion of BAC over total lung cancers [6, 7], but the
limited data from population-based cancer registries sup-
port the lack of a trend in incidence [5, 8]. Speciﬁc features
of the epidemiology of BAC include a comparable inci-
dence in men and women (in several series the number of
female cases outnumber that of male cases), a shift in the
distribution toward early-stage lesions, and a better sur-
vival rates than for other histological types of lung cancer,
which is not fully explained by differences in stage at
diagnosis [9].
The rarity of this histological type complicates the
analysis of its risk factors. A lower proportion of smokers
among BAC cases when compared to other types of lung
cancer has been reported in early studies [9–12], but only
two epidemiological studies have provided a formal esti-
mate of the risk of BAC among smokers relative to non-
smokers. In a study of 87 cases from several US hospitals,
Morabia and Wynder [13, 14] reported an odds ratio (OR)
of BAC for current smoking of 3.9 (95% conﬁdence
interval 1.8, 8.7), an increase in OR for increasing duration
and amount of smoking, and a protective effect of quitting.
In a study of 21 cases from Louisiana, Falk and colleagues
[5] reported an OR of 4.0 (95% CI 0.9, 18.8) for ever
smoking. Other risk factors have not been adequately
investigated.
Pooled analyses within a consortium of data collected in
independently conducted studies represent a cost effective
approach in generating a large series of cases and controls.
We have therefore conducted a pooled analysis of tobacco
smoking and risk of BAC within the framework of the
International Lung Cancer Consortium (ILCCO), which
includes completed and ongoing studies of molecular and
genetic epidemiology of lung cancer [15], with the aim of
providing a precise measurement of the association
between tobacco smoking and BAC.
Methods
This pooled analysis comprises data from seven case–
control studies from the United States (Table 1). These
studies represent a subset of studies included in the ILCCO
collaboration (http://ilcco.iarc.fr). The remaining studies
participating in the ILCCO consortium either excluded by
design rare histological types of lung cancer or enrolled
less than 10 BAC cases. The seven studies included one
study each from the University of California at Los
Angeles (UCLA) [16], Harvard University (HU) [17],
University of Hawaii (UH) [18], two studies from Wayne
Table 1 Characteristics of studies included in the pooled analysis of lung bronchioloalveolar carcinoma and tobacco smoking
Study, location Study
design
Deﬁnition of ever
smoker (cigarettes)
Response rate
(%) in ca/co
Total number
of lung cancer cases
Number of
BAC cases
Number
of controls
Special
features
UCLA, Los Angeles [16] Population-based [100 39/79 611 39 1,040
HU, Boston [17] Hospital-based [100 85/55 2,253 204 1,529
UH, Honolulu [18] Population-based [185 64/62 635 38 588
WSU1, Detroit [19] Population-based C100 55/71 526 50 460 Women
WSU2, Detroit [20, 21] Population-based C100 66/93 1,006 35 1,184 EO
Mayo [22] Hospital-based C100 87/84 5,698 280 2,269
AHF [23, 24] Hospital-based C100 92/93 5,130 153 4,942
BAC bronchioloalveolar carcinoma, ca cases, co controls, EO early-onset cases
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123State University (WSU) [19–21], one study from Mayo
Clinic (Mayo) [22], and one multicentric study coordinated
by the American Health Foundation (AHF) [23, 24].
Results on tobacco smoking and BAC risk have been
reported for part of the AHF study [13, 14]. For some of the
studies, the number of subjects included in the pooled
analysis was larger than that reported in previous publi-
cation because recruitment has continued. Three studies
[17, 22, 23] was hospital-based, and the other four were
community-based case–control studies. In the UCLA
study, newly diagnosed cases were identiﬁed using the
rapid ascertainment system of the Cancer Surveillance
Program for Los Angeles County. All BAC cases were
diagnosed pathologically and validated through pathologic
records. A similar approach was followed in the WSU
studies, based on the Metropolitan Detroit Cancer Sur-
veillance System. In the HU study, cases were enrolled
from the Massachusetts General Hospital in Boston, MA,
as part of an ongoing case–control molecular epidemiology
study of lung cancer. Pathology reports generated by two
pulmonary pathologists as part of routine tissue diagnosis
were obtained from the clinical information system. The
histological conﬁrmed diagnosis of BAC from pathological
reports was reviewed by a study pathologist or oncologist.
In the UH study, pathology records were obtained from
SEER registries; BAC diagnoses were not validated. In
the Mayo study, the histological diagnoses were validated.
In the AHF study, information on histology was abstracted
from the records of the pathology departments of the
participating hospitals and was not validated. The propor-
tion of BAC over total lung cancers varied from 3 to 9%.
Information on stage of BAC cases was not available.
All studies collected information on lifetime history of
tobacco smoking, including age of start smoking, duration,
intensity, and time since quitting for the former smokers.
All studies collected information on cigarette smoking; in
the UCLA, Harvard, and Hawaii studies, cigar and pipe
smoking was added to cigarette smoking to calculate
cumulative tobacco consumption. For the purposes of the
pooled analysis, we generated common variables related to
smoking status (never, ever, current, and former smoker,
deﬁned as smokers who have quit more than 1 year before
diagnosis or interview), daily amount of smoking (1–9,
10–19, 20–29, 30–39, and 40 or more cigarettes/day),
duration of smoking (1–9, 10–19, 20–29, 30–39, and 40 or
more years), and cumulative smoking (1–9, 10–19, 20–29,
30–39, and 40 or more pack years, one pack year being
equivalent to 20 cigarettes/day smoked during 1 year).
Former smokers were further categorized according to time
since quitting (1–9 years, 10–19, 20 or more years).
Other variables included in the pooled analysis were
sex, age at diagnosis or interview (categorized as up to 50,
51–60, 61–70, and more than 70), education (basic or
elementary, up to high school, and college or more), study
center, and race (Asian, Black, White, Hawaiian, Hispanic,
other).
All analyses were performed using the STATA statisti-
cal package [25]. Study-speciﬁc OR of lung cancer and
their 95% CI for smoking intensity, duration, cumulative
smoking, and time since quitting were estimated using
unconditional logistic regression. All the estimates were
adjusted for age at diagnosis, sex, race and study center.
We explored the heterogeneity between study–speciﬁc
results using the Q statistic at the signiﬁcance level of
p\0.05. Galbraith plot where the ratio of the log odds
ratio to the standard error (the Z statistic) for each study is
plotted against the reciprocal of the standard error [26].
Further, the inﬂuence of each study on the overall meta-
analysis estimate was analyzed by an inﬂuence analysis,
where the meta-analysis estimates are computed after
omitting each study. Pooled OR estimates stratiﬁed by sex,
age at diagnosis, education level, and study design were
also calculated.
Linear trends for the amount, duration, cumulative
smoking, and time since quitting were tested according to
Greenland and Longnecker [27], using the ‘glst’ command
on STATA, which utilizes the generalized least squares for
trend estimation of summarized dose–response data. Pop-
ulation attributable fractions were calculated using ‘aﬂogit’
on STATA, which estimates the adjusted measures of
population attributable fraction from a logistic regression
model [28].
Results
Overall, 799 cases of BAC and 15,859 controls were
included in the pooled analysis. Their demographic char-
acteristics are summarized in Table 2. A total of 514 cases
(64.3%) and 5,779 controls (48.1%) were women. The
median age of cases was 65 years (interquartile range
56–73 years) and that of controls was 56 years (inter-
quartile range: 45–65 years). Table 3 reports the results of
the analysis of tobacco smoking. The OR for ever smoking
was 2.47 (95% CI 2.08, 2.93); it was 2.51 (95% CI 2.09,
3.01) for current smoking and 2.35 (95% CI 1.90, 2.92) for
former smoking. The study-speciﬁc ORs for ever smoking
are presented in Fig. 1: they ranged from 1.12 in the UCLA
study to 3.90 in the AHF study; the p-value of the test for
between-study heterogeneity in OR was 0.01. The sum-
mary estimate of OR for BAC based on a meta-analysis
ﬁxed effects model was 2.38 (2.00, 2.85); the summary OR
based on a random-effects model was 2.20 (95% CI 1.51,
3.20). A linear trend was observed for amount of smoking
(OR for an increase in 10 cigarettes/day 1.32, 95% CI 1.27,
1.38; p-value of test for between-study heterogeneity 0.07),
Cancer Causes Control (2011) 22:73–79 75
123duration of smoking (OR for a 10-year increase 1.25, 95%
CI 1.20, 1.30; between-study heterogeneity p-value 0.01),
and cumulative smoking (OR for an increase in 10 pack
years 1.29, 95% CI 1.24, 1.34).
Table 4 presents the pooled results for ever smoking
stratiﬁed by sex, age at diagnosis, and education level. No
heterogeneity was suggested with respect to age sex or
education level. The proportion of BAC attributable to ever
smoking tobacco was 0.47 (95% CI 0.39, 0.54). It was 0.74
(95% CI 0.17, 0.66) in men and 0.37 (95% CI 0.24, 0.48) in
women.
Discussion
Our analysis adds strong evidence to the notion that BAC is
a form of lung cancer associated with tobacco smoking.
The current analysis also provides strong evidence on a
beneﬁcial effect of quitting tobacco smoking, as it has been
shown for lung cancer in general and for the major histo-
logical types [29].
Our results are quantitatively consistent with those of
the two epidemiological studies of BAC available in the
literature [5, 13, 14]: a meta-analysis of the results for
current smoking for the three studies resulted in a p-value
for heterogeneity of 0.7.
We acknowledge several limitations to our study. We
were not able to perform a systematic pathology review of
the cases, and the possibility of misdiagnosis remains open
for some cases. However, misclassiﬁcation is most likely to
occur with other forms of adenocarcinoma [4], a type of
lung cancer that is less strongly associated with tobacco
smoking than other types, and diagnoses of well-differen-
tiated lung cancer have been found to be reproducible
[30, 31]. The proportion of BAC over total lung cancer
cases varied from over 9% in the HU and WSU1 studies to
3% in the AHF study. A validation of BAC diagnosis was
Table 2 Demographic characteristics of lung bronchioloalveolar
carcinoma cases and controls included in the pooled analysis
Characteristic Cases Controls
n % n %
Sex
Men 285 35.7 6,233 51.9
Women 514 64.3 5,779 48.1
Age
\50 years 95 11.9 3,015 25.1
51–60 years 158 19.8 3,114 25.9
61–70 years 281 35.2 3,606 30.0
[70 years 265 33.2 2,277 19.0
Ethnicity
White 697 87.6 10,144 84.5
Black 35 4.4 1,002 8.3
Asian 32 4.1 341 2.8
Other 29 3.9 521 4.4
Education
Lower than high school 60 8.1 900 7.8
High school 308 41.5 5,004 43.6
College or higher 374 50.4 5,563 48.6
Table 3 Odds ratio of bronchioloalveolar carcinoma for tobacco
smoking in the pooled analysis
Cases Controls OR 95% CI
n % n %
Smoking status*
Ever smokers 600 75.1 7,229 60.3 2.47 2.08, 2.93
Current smokers 180 22.5 2,718 22.7 2.51 2.09, 3.01
Former smokers 415 51.9 4,431 36.9 2.35 1.90, 2.92
Amount of smoking*
1–9 cpd 71 9.0 1,139 9.6 1.57 1.18, 2.08
10–19 cpd 115 14.5 1,717 14.5 1.93 1.51, 2.46
20–29 cpd 208 26.2 2,213 18.7 2.93 2.38, 3.61
30–40 cpd 85 10.7 898 7.6 3.15 2.39, 4.14
40? cpd 115 14.5 1,110 9.4 3.79 2.94, 4.90
p-value for linear trend \0.001
Duration of smoking*
1–9 years 33 4.3 865 7.4 0.96 1.53, 1.75
10–19 years 82 10.7 1,241 10.6 1.98 1.30, 3.03
20–29 years 106 13.8 1,623 13.8 1.83 1.23, 2.71
30–40 years 157 20.5 1,618 13.8 2.87 2.10, 3.94
40? years 189 24.7 1,631 13.9 2.89 2.66, 3.55
p-value for linear trend \0.001
Cumulative smoking*
1–9 pack years 70 9.1 1,606 13.6 1.26 0.95, 1.67
10–19 pack years 74 9.6 1,195 10.1 1.89 1.43, 2.50
20–29 pack years 90 11.7 1,055 8.9 2.60 1.99, 3.38
30–40 pack years 85 11.0 982 8.3 2.81 2.14, 3.68
40? pack years 254 32.9 2,195 18.6 3.48 2.84, 4.26
p-value for linear trend \0.001
Time since quitting**
1–9 years 87 11.3 1,046 8.8 1.12 0.90, 1.53
10–19 years 138 17.9 1,367 11.5 1.06 0.82, 1.46
20–29 years 84 10.9 1,041 8.8 0.89 0.70, 1.14
30? years 84 10.9 910 7.7 0.83 0.63, 1.04
Never smokers 199 25.8 4,763 40.2 0.42 0.34, 0.52
p-value for linear trend \0.001
CI conﬁdence interval, cpd, cigarettes per day, n number, OR odds
ratio, adjusted for age, gender, race, and study center
* Reference category: never smokers (199 cases, 4,763 controls)
** Reference category: current smokers (180 cases, 2,718 controls)
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analysis; however, the study-speciﬁc results presented in
Fig. 1 do not suggest an important role for diagnostic
misclassiﬁcation, since the magnitude of the excess risk did
not appear to correlate with validation of pathological
diagnosis.
The lack of histological veriﬁcation also pre-empted us
from distinguishing between the two main types of BAC,
namely mucinous and non-mucinous. This is unfortunate
because the molecular alterations seem to differ between
the two types, with a higher proportion of codon 12 KRAS
mutations in the mucinous type and, conversely, a higher
proportion of TP53 mutations in the non-mucinous type
[32–35]. The high proportion of EGFR mutations in BAC,
when compared to other types of lung adenocarcinoma
[36], is consistent with a comparatively lesser etiologic role
of tobacco smoking in the former type of neoplasm.
An additional potential limitation, which is common to
retrospective epidemiological studies, is recall bias, i.e.,
lung cancer cases over-reporting tobacco smoking when
compared to controls, either because of better recall or
because they are trying to explain their disease. However,
the internal consistency of our results (dose–response
relation with amount and duration of smoking, effect of
long-term quitting, lack of heterogeneity by sex, age, or
education) argues against a strong role of recall bias.
The main strength of our study lies in its size, as it
included more than seven times the total number of BAC
cases included in previous epidemiological studies on the
effect of tobacco smoking on this form of lung cancer. The
high quality of participating studies and the validity of the
information on exposure and outcome are conﬁrmed by the
consistency of inter-study risk estimates.
No results have been reported on risk of BAC after
cessation of smoking. The available evidence points toward
a more rapid decrease in risk with increasing time since
cessation for squamous cell carcinoma than for adenocar-
cinoma [29]. The similarities between BAC and adeno-
carcinoma might explain the relatively weak effect of
quitting we observed in our analysis.
In conclusion, our pooled study resulted in a twofold
increased risk of lung BAC in ever smokers when com-
pared to never smokers, and in evidence of a dose–response
OR
.5 1 1.5 5 10 15
Combined
 AHF
 MAYO
 WSU2
 WSU1
 UH
 HU
 UCLA
Fig. 1 Study-speciﬁc odds
ratios (and 95% conﬁdence
intervals) of lung
bronchioloalveolar carcinoma
for ever tobacco smoking. The
combined odds ratio is based on
a random-effects model meta-
analysis
Table 4 Odds ratio of bronchioloalveolar carcinoma for ever tobacco
smoking in the pooled analysis, stratiﬁed by sex, age at diagnosis, and
education
Stratum OR 95% CI
Sex
Men 2.10 1.61, 2.91
Women 2.52 2.01, 3.08
Test for heterogeneity, p-value 0.87
Age
B60 years 1.48 0.97, 2.26
50–60 years 2.65 1.78, 3.95
60–70 years 2.39 1.77, 3.23
[70 years 2.73 1.99, 3.70
Test for heterogeneity, p-value 0.12
Education
Lower than college 3.05 2.35, 3.98
College of higher 2.39 1.88, 3.05
Test for heterogeneity, p-value 0.18
CI conﬁdence interval, OR odds ratio, adjusted for age, gender, race,
and study center
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123relation according to duration and amount of smoking.
Forty-seven percent of BAC cases in the study population
would be attributable to the habit. This is the most precise
estimate of the risk of BAC for tobacco smoking available
in the literature and supports the notion of an association
between tobacco smoking.
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